Pure Global
NCT05946642

Innovative Intermittent Preventive Treatment Approaches to Reduce Malaria Burden in School-age Children in Burkina Faso

Clinical Trial to Evaluate Efficacy and Safety of Sulfadoxine/Pyrimethamine-Amodiaquine and Dihydroartemsinin-Piperaquine Plus Ivermectin Administered Monthly as Intermittent Preventive Treatment in School-aged Children in Burkina Faso
Malaria Consortium·Phase 3·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Malaria
Drug/Device/Intervention
Sulphadoxine-Pyrimethamine/Amodiaquine
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Malaria Consortium
Location
Ouagadougou, Burkina Faso
Timeline & enrollment
Phase
Phase 3
Start date
Jul 15, 2023
End date
Dec 31, 2024
Enrollment
13000 participants
Primary outcome

Prevalence of symptomatic malaria in children of the target age group by microscopy and molecular methods.

Summary

This will be an open label cluster randomized study with two active intervention and one
 control arm. A cluster will be defined as a selected village. One district implementing
 seasonal malaria chemoprevention (SMC) will be selected, and six villages will be randomly
 selected in this district. These six villages will be randomly allocated to each of the three
 study arms; 1) Arm 1 will receive IPTsc with sulphadoxine-pyrimethamine plus amodiaquine
 (SPAQ); and 2) Arm 2 will receive dihydroartemisinin-piperaquine (DP) plus Ivermectin (IVM),
 all given monthly during the transmission season and 3) Control Arm which will have standard
 malaria control measures including case management and vector control measures as applicable.

ICD-10 classifications
Unspecified malariaPlasmodium malariae malariaPlasmodium falciparum malariaOther parasitologically confirmed malariaPlasmodium ovale malaria
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05946642
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05946642 through Pure Global AI's free database. This Phase 3 trial is sponsored by Malaria Consortium and is currently Not yet recruiting. The study focuses on Malaria. Target enrollment is 13000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.